Search

Search or Filter



Results

showing 1-10 of 5189






Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP

A global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, announced topline results from a large study among cisgender African women on 20 June, followed shortly thereafter with a statement about access.

Prevention Option:

July 2024


Advocates’ Primer on Lenacapavir for PrEP

Last month, early trial results showed twice a year injectable lenacapavir for PrEP was highly effective among young women. Today, AVAC introduces a brand-new primer on the potential prevention tool and a call to action from AWPCAB and CASPR that shares next steps for stakeholders and lessons learned from past PrEP implementation. Read both resources in our latest blog post.

July 2024


The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an
independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention
was safe and highly effective against HIV. No infections were seen among trial participants those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.

Prevention Option:

July 2024


Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP

A global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, announced topline results from a large study among cisgender African women on 20 June, followed shortly thereafter with a statement about access.

Prevention Option:

July 2024


GPP Body of Evidence Webinar Series

Good Participatory Practice Guidelines have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.

Prevention Option:

July 2024


showing 1-10 of 5189